FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer By Ogkologos - February 13, 2025 732 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CodeBreaK 300 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR After Being Told a Lump Was Benign, Teenager Learns She Has... August 14, 2021 Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death... October 10, 2019 Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... March 6, 2023 How We’re Working to Help People With Cancer Across the World April 7, 2021 Load more HOT NEWS Time to meet our new chief scientist – Professor KJ Patel Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... The digital shift: How are remote GP appointments affecting cancer patients? Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma
